Monkeypox virus antigens (A29L, M1R, B6R, A35R) (Mpox antigens)

The target refers to a vaccine strategy utilizing ferritin nanoparticles to display Monkeypox virus (Mpox) antigens—specifically A29L, M1R, B6R, and A35R—to the immune system. Ferritin is a ubiquitous protein that self-assembles into a highly stable, 24-subunit nanocage, providing a scaffold for the multivalent display of viral proteins [1]. By presenting these antigens in a repetitive, symmetric array, the platform mimics the viral surface, which significantly enhances B-cell receptor cross-linking and the subsequent production of high-titer neutralizing antibodies [2]. The selected antigens are critical for the Mpox life cycle: A29L and M1R facilitate viral attachment and fusion, while B6R and A35R are involved in the formation and release of the extracellular enveloped virus (EEV) [3]. This multivalent approach aims to provide comprehensive protection by targeting both the intracellular mature virus (IMV) and EEV forms of the virus [4]. Currently, this technology is being leveraged in the development of next-generation vaccines to address the global health threat posed by Mpox and related orthopoxviruses [5].

Other names

Mpox surface proteinsOrthopoxvirus antigensFerritin-nanoparticle Mpox antigensMonkeypox virus structural proteins

Induction of neutralizing antibodies and cellular immune responses through multivalent antigen presentation on a ferritin scaffold.